Format

Send to

Choose Destination
Cancer Genomics Proteomics. 2019 Sep-Oct;16(5):353-359. doi: 10.21873/cgp.20140.

MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients.

Author information

1
Masaryk University, Central European Institute of Technology, Brno, Czech Republic.
2
Masaryk Memorial Cancer Institute, Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
3
Department of Clinical Oncology and Radiotherapy, University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic.
4
Department of Oncology and Radiotherapeutics, Medical School and Teaching Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
5
Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
6
Masaryk Memorial Cancer Institute, Department of Oncological and Experimental Pathology Faculty of Medicine, Masaryk University, Brno, Czech Republic.
7
Institute for Biostatistics and Analyses, Masaryk University, Brno, Czech Republic.
8
Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.
9
Masaryk Memorial Cancer Institute, Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic on.slaby@gmail.com.

Abstract

BACKGROUND/AIM:

Sunitinib is a tyrosine kinase inhibitor routinely used as first-line therapy in metastatic renal cell carcinoma (mRCC). Emerging evidence suggests that microRNAs (miRNAs) could be suitable biomarkers with predictive potential in mRCC. The aim of this study was to identify miRNA-based predictive biomarkers of therapy response to avoid unnecessary therapy to non-responding patients.

PATIENTS AND METHODS:

High-throughput miRNA microarray profiling was performed on a cohort of 47 patients treated with sunitinib. Validation of candidate miRNAs was carried out on an independent cohort of 132 mRCC patients using qRT-PCR.

RESULTS:

Out of 158 miRNAs (65 down-regulated, 93 up-regulated), six miRNAs were chosen for independent validation and miR-376b-3p was confirmed to be differentially expressed in tumors of patients with primary resistance versus long-term response (p<0.0002).

CONCLUSION:

A predictive miRNA associated with progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib was identified.

KEYWORDS:

Renal cell carcinoma; microRNA; prediction; sunitinib

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center